ACADIA Pharmaceuticals Inc. $ACAD Stock Position Raised by Fisher Asset Management LLC

Fisher Asset Management LLC grew its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 105.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 638,492 shares of the biopharmaceutical company’s stock after acquiring an additional 328,181 shares during the period. Fisher Asset Management LLC owned 0.38% of ACADIA Pharmaceuticals worth $13,625,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Marshall Wace LLP boosted its holdings in ACADIA Pharmaceuticals by 496.2% in the second quarter. Marshall Wace LLP now owns 1,969,711 shares of the biopharmaceutical company’s stock worth $42,487,000 after purchasing an additional 1,639,315 shares in the last quarter. Norges Bank acquired a new position in shares of ACADIA Pharmaceuticals during the 2nd quarter valued at about $31,679,000. Adage Capital Partners GP L.L.C. bought a new position in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at approximately $13,024,000. Candriam S.C.A. acquired a new stake in ACADIA Pharmaceuticals in the 3rd quarter worth approximately $11,472,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in ACADIA Pharmaceuticals in the 2nd quarter worth approximately $7,257,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock opened at $23.39 on Thursday. The firm has a market cap of $3.99 billion, a PE ratio of 10.21, a P/E/G ratio of 19.00 and a beta of 0.66. The business’s 50 day simple moving average is $25.23 and its 200 day simple moving average is $24.40. ACADIA Pharmaceuticals Inc. has a 52-week low of $13.40 and a 52-week high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $1.48. The business had revenue of $298.00 million during the quarter, compared to the consensus estimate of $292.54 million. ACADIA Pharmaceuticals had a net margin of 36.49% and a return on equity of 12.49%. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.86 earnings per share. As a group, equities research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.

More ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: JPMorgan upgraded ACAD to “overweight” and raised its price target from $31 to $34, implying substantial upside versus the current share level — a clear catalyst for buying interest. Benzinga
• Positive Sentiment: Analyst consensus remains constructive — ACAD was reported as having an average rating of “Moderate Buy,” which supports positive sentiment among institutional and retail investors. Analyst Note
• Positive Sentiment: Board addition — Acadia appointed Jonathan M. Poole to its board and audit committee, bringing experienced biopharma finance leadership that may strengthen governance and strategic financial oversight. Business Wire
• Neutral Sentiment: Short-interest reports in early March show zeros/NaN and a 0.0 days ratio — the published data appears erroneous or non-informative and should not be treated as a reliable signal without corrected filings. (Reports flagged on March 3–4.)
• Negative Sentiment: European regulatory setback — the CHMP recommended against approval of Daybue for Rett syndrome in the EU. Acadia is pursuing a CHMP re-examination, but the rejection and the resulting delay introduce regulatory risk and could push out EU revenue expectations. Zacks FiercePharma MarketWatch

Insider Activity at ACADIA Pharmaceuticals

In related news, EVP Jennifer J. Rhodes sold 6,950 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $23.38, for a total value of $162,491.00. Following the sale, the executive vice president owned 7,609 shares in the company, valued at approximately $177,898.42. This represents a 47.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 26.50% of the company’s stock.

Analysts Set New Price Targets

ACAD has been the topic of several research analyst reports. Oppenheimer reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Friday, February 6th. Citizens Jmp raised their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Wall Street Zen lowered ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. TD Cowen raised their price objective on shares of ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $34.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.21.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.